Boston Scientific Corp

BSX is locked in a broad downtrend under declining moving averages with no clear reversal setup. Medium-term directional bias remains bearish as price trades below the 50-day SMA and failed consolidations stall at overhead EMAs. Short-term conditions are neutral in a tight EMA9/20 range without exhaustion signals, suggesting deferment. We will trim into rallies near the converged short EMAs and watch for a decisive break of support or a rejection at resistance to re-assess the trend.

• ↑Q2 2026 revenue $5.44B (+7.5%) and adjusted EPS $0.86 (+15%)
• ↑2026 organic revenue guide 10–11% bolstered by cardiology and neuromodulation launches
• ↓2026 guidance cut trims Watchman and EP organic growth to 5–7%